Search Results for “diagnostic” – Page 68 – media

Medtronic secures FDA approval for Intellis spinal cord stimulator

Medtronic has secured the US Food and Drug Administration (FDA) approval for its next generation spinal cord stimulator branded as Intellis platform for the management of certain forms of chronic intractable pain.
- Source: medicaldevices-business-review
- 1,001
- September 21, 2017
chronic Company Insight spinal cord stimulator
Pear Therapeutics Wins FDA Nod for the First-Ever Medical App for Treating Drug Addiction

The U.S. Food and Drug Administration(FDA) permitted marketing of the first mobile medical application to help treat substance use disorders (SUD). The Reset application is intended to be used with outpatient therapy to treat alcohol, cocaine, marijuana and stimulant SUDs. The application is not intended to be used to treat opioid dependence.
- Source: Biospace
- 632
- September 18, 2017
FDA substance use disorders
Medical Trade Exhibitions in September — Global Product Promotions from the Comfort of Your Own Home!

Since the launch of the Ddu Global Promotion Plan, Ddu has succeeded in helping users do international product promotions without leaving home and has matched thousands of orders, rapidly gaining popularity in the medical trade industry. The upcoming exhibitions of Ddu’s Global Promotion Plan include Thailand, Vietnam, Azerbaijan and Argentina!
- Source: Ddu
- 609
- September 15, 2017
Argentina Azerbaijan Exhibitions & Activities Thailand
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD® had revenues of approximately $168 million for the trailing twelve month period ending June 30, 2017. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively.
- Source: finance.yahoo
- 531
- September 13, 2017
Company Insight Market Views oncology PARAGARD
National Hospitalist Conference

The National Hospitalist Conference will be held in Santa Fe, New Mexico at the Eldorado Hotel & Spa on September 8-10, 2017. The National Hospitalist Conference is designed to provide physicians, physician assistants, and nurse practitioners with information and skills to improve the care of their hospitalized patients.
- Source: medical-events
- 643
- September 8, 2017
Exhibitions & Activities hospitalized
LabCorp completes $1.2B Chiltern buy

Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International.
- Source: drugdeliverybusiness
- 667
- September 4, 2017
acquisition Clinical Market Views oncology
MedGenome raises $30m for biomarker discovery program

MedGenomeGenomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round.
- Source: drugdeliverybusiness
- 612
- August 30, 2017
genetic immunotherapy Market Views Series
Patterson Dental, Align Technology sign distribution deal for intraoral scanning system

A distribution agreement for Align’s iTero Element intraoral scanning system has been signed between Patterson Dental, a business unit of Patterson Companies, and Align Technology.
- Source: medicaldevices-business-review
- 510
- August 25, 2017
Company Insight digital Market Views scanning
Siemens gets CE-Mark for MR scanner Magnetom Terra

Siemens Healthineers has received CE-Mark for its ultra-high-field 7T magnetic resonance (MR) scanner Magnetom Terra, making it available for neurological and musculoskeletal clinical examinations in Europe.
- Source: medicaldevice
- 541
- August 24, 2017
Clinical MR musculoskeletal neurological
HeartSciences gets CE mark for MyoVista hsECG testing device

MyoVista hsECG testing device has been developed for front-line screening of cardiac disease in both symptomatic and asymptomatic patients.
- Source: medicaldevices
- 607
- August 21, 2017
cardiac CE Company Insight CWT hsECG

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.